前列腺癌患者报告的生活质量与生存结局:ECOG-ACRIN E3805 化学激素联合雄激素剥夺随机试验(CHAARTED)分析
该探索性事后分析纳入790例转移性激素敏感性前列腺癌(mHSPC)患者,评估生活质量(QOL)与总生存(OS)的关系。3个月时FACT-P较高与生存改善独立相关(HR 0.76,p=0.05);基线及3个月QOL最差四分位患者接受ADT+多西他赛较单用ADT生存更长,而QOL最好四分位患者未显示获益。
要点
- 3个月时FACT-P较高与更好的生存独立相关(HR 0.76,p=0.05)。
- 基线及3个月QOL最差四分位患者,ADT+多西他赛较单用ADT中位OS更长。
- 基线及3个月QOL最好四分位患者,加用多西他赛与否生存无显著差异。
核心结论
- 3个月QOL与生存的独立关联更强,症状最重的患者加用多西他赛后生存更长,而症状最轻的患者似乎未获益。
- 考虑QOL可能有助于在mHSPC选择化学激素治疗时改善决策和患者选择。
研究设计与样本
- 该研究为探索性事后分析,纳入790例mHSPC患者,完成FACT-P、FACIT-F和BPI生活质量量表。
- 采用对数秩检验和Cox比例风险模型,按临床和疾病特征检验QOL与OS的关联。
主要发现
- 基线FACT-P较高在校正临床变量后趋势向好但未达统计学显著(HR 0.80 [0.62, 1.04],p=0.09)。
- 3个月FACT-P较高与更好的生存独立相关(HR 0.76 [0.58, 1.0],p=0.05)。
- 基线QOL最差四分位患者接受ADT+多西他赛较单用ADT中位OS 45.2 vs 34.4个月(HR 0.75 [0.53, 1.05],p=0.09)。
- 3个月QOL最差四分位患者接受ADT+多西他赛较单用ADT中位OS 48.3 vs 29.3个月(HR 0.69 [0.48, 0.99],p=0.05)。
- 基线QOL最好四分位患者加用多西他赛与否中位OS 72.1 vs 51.7个月(HR 0.92 [0.63, 1.36],p=0.69),3个月QOL最好四分位患者中位OS 69.9 vs 68.9个月(HR 1.11 [0.73, 1.67],p=0.63)。
关键数值与推荐
- 生存与基线FACIT-F相关(HR 0.76 [0.57, 1.0],p=0.05),但与BPI无关(HR 0.98 [0.75, 1.28],p=0.90)。
临床怎么用
- 作者认为,考虑QOL可能有助于在mHSPC选择化学激素治疗时改善决策和患者选择。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chemohormonal therapy with androgen deprivation therapy and docetaxel (ADT + D) improves overall survival (OS) and quality of life (QOL) at 12 mo versus androgen deprivation therapy (ADT) alone in men with metastatic hormone-sensitive prostate cancer (mHSPC). However, the prognostic role of QOL is unknown in this population. OBJECTIVE: To study the relationship between QOL, disease characteristics, and OS in men with mHSPC. DESIGN, SETTING, AND PARTICIPANTS: In this exploratory post hoc analysis, 790 patients with mHSPC completed the QOL instruments Functional Assessment of Cancer Therapy-Prostate (FACT-P), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), and Brief Pain Inventory (BPI). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Log-rank test and Cox proportional hazard models tested the association between QOL and OS by clinical and disease characteristics. RESULTS AND LIMITATIONS: Baseline higher FACT-P trended toward improved survival after accounting for clinical variables (hazard ratio [HR] 0.80 [0.62, 1.04], p = 0.09), while higher 3-mo FACT-P was independently associated with better survival (HR 0.76 [0.58, 1.0], p = 0.05). Patients with the poorest QOL (bottom quartile) at baseline and 3 mo had longer survival if they received ADT + D rather than ADT alone (median OS 45.2 vs 34.4 mo, HR 0.75 [0.53, 1.05], p = 0.09, and 48.3 vs 29.3 mo, HR 0.69 [0.48, 0.99], p = 0.05 respectively). In contrast, patients with the best QOL (top quartile) at baseline and 3 mo had comparable survival irrespective of whether or not docetaxel was added (median OS 72.1 vs 51.7 mo, HR 0.92 [0.63, 1.36], p = 0.69, and 69.9 vs 68.9 mo, HR 1.11 [0.73, 1.67], p = 0.63, respectively). Survival was linked with baseline FACIT-F (HR 0.76 [0.57, 1.0], p = 0.05), but not BPI (HR 0.98 [0.75, 1.28], p = 0.90). CONCLUSIONS: Three-month QOL had a stronger independent association with survival. The most symptomatic patients had longer survival with the addition of docetaxel; conversely, the least symptomatic patients did not appear to benefit. Consideration of QOL may enhance decision-making and patient selection when choosing chemohormonal treatment in mHSPC. PATIENT SUMMARY: Quality of life independently forecasted the survival of men with metastatic hormone-sensitive prostate cancer in the CHAARTED study. Close tracking of quality of life could help patients and clinicians make decisions about the appropriate treatment in this setting.
引用
- Sentana-Lledo D, Chu X, Jarrard DF, et al. Patient-reported Quality of Life and Survival Outcomes in Prostate Cancer: Analysis of the ECOG-ACRIN E3805 Chemohormonal Androgen Ablation Randomized Trial (CHAARTED). Eur Urol Oncol. 2024. PMID: 38688766. doi:10.1016/j.euo.2024.04.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。